EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

Safety of Re-dosing Nirsevimab Prior to RSV Season 2 in Children With Heart or Lung Disease

Joseph B Domachowske, Yue Chang, Victoria Atanasova, Fernando Cabañas, Kenji Furuno, Kim A Nguyen, Irfana Banu, Robert J Kubiak, Amanda Leach, Vaishali S Mankad, Manish Shroff, Therese Takas und 2 weitere

Journal of the Pediatric Infectious Diseases Society · 2023

DOI: 10.1093/jpids/piad052 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Journal of the Pediatric Infectious Diseases Society, 2023. Verfasst von Joseph B Domachowske und 13 weiteren Autor:innen. Beteiligte Einrichtung: Department of Pediatrics, SUNY Upstate Medical University, Syracuse, New York, USA. Hauptthemen laut MEDLINE: Respiratory Syncytial Virus Infections, Respiratory Syncytial Virus, Human, Lung Diseases. Die Arbeit wurde bisher 35-mal zitiert (Crossref) und nennt 8 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: AstraZeneca, Sanofi.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

In children with congenital heart disease and/or chronic lung disease entering their second respiratory syncytial virus (RSV) season, 200 mg nirsevimab had a similar safety profile to that of palivizumab and resulted in nirsevimab serum exposures associated with efficacy in healthy infants, supporting efficacy in this population at risk of severe RSV disease.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Respiratory Syncytial Virus InfectionsRespiratory Syncytial Virus, HumanLung DiseasesInfantChildHumansAntibodies, MonoclonalAntiviral AgentsSeasonsAntibodies, Monoclonal, Humanized

Stichwörter der Autor:innen

monoclonal antibodynirsevimabpalivizumabpharmacokineticsrespiratory syncytial virus

Substanzen

Antibodies, MonoclonalAntiviral AgentsnirsevimabAntibodies, Monoclonal, Humanized

Autor:innen und Institutionen

  • Department of Pediatrics, SUNY Upstate Medical University, Syracuse, New York, USA.
  • Vaccines & Immune Therapies, Biopharmaceuticals R&D, AstraZeneca, Gaithersburg, Maryland, USA.
  • UMHAT Dr. G. Stranski EAD, Clinic of Neonatology, Pleven, Bulgaria.
  • Department of Paediatrics-Neonatology, Quironsalud Madrid University Hospital and Quironsalud San José Hospital, Madrid, Spain.
  • Department of General Pediatrics and Interdisciplinary Medicine, Fukuoka Children's Hospital, Fukuoka, Japan.
  • Hospices Civils de Lyon, Hôpital Femme-Mere-Enfant, Service de Réanimation Néonatale et de Neonatologie (NICU) et CIC 1407, Lyon, France.

Förderung

  • AstraZeneca
  • Sanofi

Zitieren

APA

Domachowske, J. B., Chang, Y., Atanasova, V., Cabañas, F., Furuno, K., Nguyen, K. A., Banu, I., Kubiak, R. J., Leach, A., Mankad, V. S., Shroff, M., Takas, T., Villafana, T., & Wählby Hamrén, U. (2023). Safety of Re-dosing Nirsevimab Prior to RSV Season 2 in Children With Heart or Lung Disease. Journal of the Pediatric Infectious Diseases Society. https://doi.org/10.1093/jpids/piad052

Vancouver

Domachowske JB, Chang Y, Atanasova V, Cabañas F, Furuno K, Nguyen KA, et al. Safety of Re-dosing Nirsevimab Prior to RSV Season 2 in Children With Heart or Lung Disease. Journal of the Pediatric Infectious Diseases Society. 2023. doi:10.1093/jpids/piad052

BibTeX
@article{Domachowske2023,
  author = {Domachowske, Joseph B and Chang, Yue and Atanasova, Victoria and Cabañas, Fernando and Furuno, Kenji and Nguyen, Kim A and Banu, Irfana and Kubiak, Robert J and Leach, Amanda and Mankad, Vaishali S and Shroff, Manish and Takas, Therese and Villafana, Tonya and Wählby Hamrén, Ulrika},
  title = {Safety of Re-dosing Nirsevimab Prior to RSV Season 2 in Children With Heart or Lung Disease},
  journal = {Journal of the Pediatric Infectious Diseases Society},
  year = {2023},
  doi = {10.1093/jpids/piad052}
}
Kostenlos starten →